Targeted Genetics Regains Momentum Following Clinical Trial Hold For Biologic
This article was originally published in The Pink Sheet Daily
Executive Summary
Seattle-based firm presents data suggesting supplemental therapeutic tgAAC94 did not contribute to subject’s death during clinical trial.